22 December 2010
Artificial Liver Support: Quo Vadis?
Jacek Rozga, Piotr MalkowskiAnn Transplant 2010; 15(4): 92-101 :: ID: 881357
Abstract
ABSTRACT: Background: Approximately 2 million persons worldwide die each year from hepatic failure. Because of the scarcity of donor organs, artificial liver support systems are being developed with the aim of either supporting patients with borderline functional liver cell mass until an appropriate organ becomes available for transplantation or until their livers recover from injury. Material/Methods: A literature review was performed using MEDLINE, PubMed, EMBASE, and library searches. Only major liver support techniques are included in this review. Results: A number of extracorporeal liver assist systems are in various stages of clinical development. Published data indicate that patients with acute and acute-on-chronic liver failure may benefit from treatment with some of these therapeutic measures. Results from large prospective randomized trials have shown that treatment with MARS® and PROMETHEUS® may not confer a survival advantage, despite positive effects on blood toxemia and improvement in hepatic encephalopathy. Currently, hemofiltration using albumin-leaking membranes is being explored as a novel promising approach to blood purification in liver failure. Conclusions: Developing an effective liver assist technology has proven difficult, because of the complexity of liver functions that must be replaced, as well as heterogeneity of the patient population. Non-biological systems may have a role in the treatment of specific forms of liver failure where the primary goal is to provide blood detoxification/purification. Biological systems appear to hold promise for treating liver failure where the primary objective is to provide whole liver functions which are impaired or lost.
Keywords: artificial liver support, Liver failure, detoxification, blood purification, albumin
In Press
04 Aug 2022 : Original article
Long-Term Patency of All-in-One Sleeve Patch Graft Venoplasty in 16 Patients Who Underwent Living Donor Liv...Ann Transplant In Press; DOI: 10.12659/AOT.936888
22 Jul 2022 : Original article
Diagnostic Role of Tumor Markers for Hepatocellular Carcinoma in Liver Transplantation Candidates: An Analy...Ann Transplant In Press; DOI: 10.12659/AOT.936937
22 Jul 2022 : Original article
Development of a Novel Model for Predicting Postoperative Short-Term Outcome in Patients with Hepatitis B-R...Ann Transplant In Press; DOI: 10.12659/AOT.936732
22 Jul 2022 : Original article
Leucine-Rich Alpha-2-Glycoprotein (LRG-1) as a Potential Kidney Injury Marker in Kidney Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.936751
Most Viewed Current Articles
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
24 Jul 2020 : Review article
Kidney Transplantation in the Times of COVID-19 – A Literature ReviewDOI :10.12659/AOT.925755
Ann Transplant 2020; 25:e925755
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860